Skip to main content
Premium Trial:

Request an Annual Quote

NY State Approves Columbia's Cancer Gene Panel

NEW YORK (GenomeWeb) – The New York State Department of Health has approved Columbia University Medical Center's 467-gene targeted sequencing cancer test, the university said today.

Columbia runs its test on the Illumina HiSeq 2500 out of its CLIA-certified, CAP-accredited Laboratory of Personalized Genomic Medicine. It will run the test on fresh or frozen tissue samples, as well as formalin-fixed paraffin-embedded tissue.

Aside from the 467-gene test, Columbia also has New York approval for its TruSeq Targeted Cancer Panel, which analyzes mutations in 48 genes. Its cancer exome and transcriptome tests are available on a case-by-case basis while the university medical center waits for state approval. The lab also offers a 46-gene targeted panel; a number of single-gene tests, including for KRAS and EGFR; clonality testing; BCR-ABL quantitative testing by RT-PCR; MGMT methylation analysis; and EGFRviii RNA expression.

Last year, the lab received NY State approval for its diagnostic exome test for inherited disorders.